Not FDA-approved
Bones & muscles
IGF-1 DES
Evidence
Limited human data
Class
Truncated IGF-1 variant
KEY TAKEAWAY
IGF-1 DES is a version of IGF-1 that is missing its first three amino acids. This change helps it avoid binding proteins in the blood. IGF-1 DES is not FDA-approved and has not been tested in controlled human trials as a drug.
Written by the Veylo editorial team · Updated
November 2026
What it is
Truncated IGF-1 variant
Main uses
Studied in cell and animal models of tissue growth; sold online for muscle growth
Key fact
IGF-1 DES is not FDA-approved and has not been tested in controlled human trials as a drug.
Route
Usually injected in animal studies
Evidence strength
Limited human data
IGF-1 DES is a version of IGF-1 that is missing its first three amino acids. This change helps it avoid binding proteins in the blood.
It binds the IGF-1 receptor more freely than full-length IGF-1, so it acts locally and for a shorter time.
IGF-1 DES is not FDA-approved and has not been tested in controlled human trials as a drug.
Studied in cell and animal models of tissue growth; sold online for muscle growth.
Low blood sugar and unwanted tissue growth are theoretical concerns. Human safety data do not exist.
IGF-1 DES: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.